Cipla seeks to increase its presence in the American market; aims to launch several products in the second half of 2022

Pharma major Cipla is known as the Robinhood of the pharmaceutical industry. The company is best known for changing the market for HIV drugs in Africa by bringing the prices of HIV drugs down to less than a dollar a day.

More recently, Cipla was known for having one of the most comprehensive COVID-19 portfolios – from tocilizumab to remdesivir to favipiravir.

Cipla, the third largest pharmaceutical company in India, present in more than 80 countries with more than 46 manufacturing sites, is now focusing more on complex drugs that are difficult to manufacture and injectables in segments such as respiratory and cancer. . The company is also looking to increase its presence in the United States.

To discuss growth prospects, CNBC-TV18 spoke with Umang Vohra, MD and Global CEO of Cipla.

Watch the video to learn more.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button